BofA lowered the firm’s price target on Ultragenyx (RARE) to $79 from $80 and keeps a Buy rating on the shares. Ultragenyx announced they have received a complete response letter from the FDA regarding their application for UX111 in Sanfilippo syndrome highlighting that the agency did not have issues with the clinical data package but requested additional information and improvements related to chemistry, manufacturing and controls, the analyst tells investors in a research note. BofA looks for color on the scheduling of the Type A meeting as well as clarity on potential readthrough to the company’s other gene therapy programs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Positive Outlook on Ultragenyx Pharmaceutical Despite Setback with UX111 Approval
- Ultragenyx announces Health Canada extended approval of Evkeeza
- Ultragenyx price target lowered to $55 from $65 at Morgan Stanley
- Ultragenyx falls 4% to $28.41 after FDA rejection letter for gene therapy
- Ultragenyx Receives FDA Response on UX111 Application